Compare IVR & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVR | ANNX |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.4M | 812.7M |
| IPO Year | N/A | 2020 |
| Metric | IVR | ANNX |
|---|---|---|
| Price | $7.58 | $5.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $8.25 | ★ $16.50 |
| AVG Volume (30 Days) | 2.8M | ★ 4.7M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 17.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $150.63 | N/A |
| Revenue Next Year | N/A | $16,320.74 |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.10 | $2.03 |
| 52 Week High | $9.50 | $7.18 |
| Indicator | IVR | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 44.36 |
| Support Level | $7.13 | $4.66 |
| Resistance Level | $7.93 | $5.65 |
| Average True Range (ATR) | 0.16 | 0.50 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 6.06 | 15.12 |
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.